Creating value in the lives of the people we serve, now and into the future

UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.

Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge

UCB share price

Financial Guidance

The figures of the guidance 2025 as mentioned below were calculated on the same basis as the actual figures for 2024 and based on current rules and regulations.

2025 Revenue

€ 6.5-6.7bn

Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®, despite impact of 340B and IRA across portfolio. 
CIMZIA® volume growth expected to be overcompensated by pricing pressure

2025 adj. EBITDA 

30%

Continued gross margin improvement, operating leverage improvement, continued growth of marketing and sales expenses driven by top-line growth and relatively stable R&D expenses and continued EVENITY® earnings contribution

2025 Core EPS

€ 6.80 - 7.40

based on an average of 190 million shares outstanding

 

Upcoming Events

JP Morgan - CEO Call series

Virtual

BofA - Global Healthcare Conference

London

KCB Life Sciences Conference

Brussels

Latest News

Latest Documents

2024 Half-Year Report

Download here
2023 Integrated Annual Report

Download here
View more

Financial Calendar

2025 Half-Year Results

Contact UCB IR Team

investor-relations@ucb.com or a specific team member:

Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com



Sahar Yazdian, Investor Relations Lead

Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com

UCB IR App